Eli Lilly will open a new drug delivery and device innovation center in Cambridge, MA. Medical devices aren't a focus for the pharma now--but it noted that more than half of its current pipeline candidates are biologics that require injection. It expects to double its revenues from device-enabled products by 2020 and is looking to have a hand in that arena.
Researchers in the lab of MIT's Robert Langer have created a hydrogel that's designed to be much better than current technologies in getting drugs into patients and straight to where they are targeted.
Montreal-based enGene has lined up $11.5 million in venture financing to put its next-gen approach to an inflammatory bowel disease treatment through its first clinical test.
Medical device giant Medtronic said it reached another milestone in developing an artificial pancreas with the completion of global evaluations of its new insulin delivery system.
Bind Therapeutics believes its lead nanoparticle treatment can make a difference for a subgroup of lung cancer patients, pointing to some positive results from an otherwise mixed mid-stage trial as it prepares for further study.
Billing it as the most important new innovation in the interferon drug class in a decade, Biogen Idec nailed down the FDA's approval of Plegridy, a new multiple sclerosis drug that patients can easily inject themselves with once every two weeks.
Shares of AcelRx took a painful 30% plunge on Monday morning as investors got a chance to respond to the biotech's announcement late Friday night that the FDA had rejected its application for Zalviso, its sufentanil sublingual microtablet drug/device system for fighting pain.
San Diego biotech Otonomy isn't biding its time, filing to go public in an $86.3 million IPO just three days after unveiling positive Phase III results for its lead drug.
Aprecia has an MIT-licensed method of 3-D printing pills and a plan to hit the market with easy-to-take formulations of top-selling medicines. To get there, the biotech has tapped CRO inVentiv Health, which is on hand to lend its commercialization expertise.
Baxter is buying out collaborator Chatham Therapeutics for $70 million, planning to absorb the gene therapy specialist into its growing hemophilia R&D operation as it prepares to separate its drug and device businesses next year.